The IRA's Pill Penalty: Why Washington Just Told Biotech to Go Biologic

The Inflation Reduction Act didn't just let Medicare negotiate drug prices — it wrote a structural bias into which drugs get negotiated first. Small-molecule pills become eligible for price-setting nine years after FDA approval; biologics get a 13-year runway. That four-year gap — the "pill penalty" — falls exactly in the window (years 10-14) when a drug typically earns half its lifetime revenue. Capital allocators inside pharma have noticed, and so has R&D: money is quietly rotating toward biologics, where the government waits longer to touch the price tag. This isn't a rumor or a lobbying talking point — it's baked into the Social Security Act's negotiation-eligibility timeline (42 U.S.C. 1320f-1) and it compounds every single year the exemption goes unfixed.